[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Karyopharm Therapeutics Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":35,"locationsCount":4},"100609534","karyopharm-expanded-access-program-for-selinexor-100609534",false,"NCT07215832","Karyopharm Expanded Access Program for Selinexor","KEAP","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","ALL","EXPANDED_ACCESS","KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.",[20,21,22,23,24,25,26,27],"Multiple Myeloma","Diffuse Large B-Cell Lymphoma (DLBCL)","Sarcoma","Neuroglioblastoma","Peripheral T-cell Lymphoma","Endometrial Cancer","Myelofibrosis","Other",[29],"selinexor","AVAILABLE","2026-02-26",{"date":33,"type":34},"2026-03-02","ACTUAL",{"name":36,"class":37},"Karyopharm Therapeutics Inc","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100514615","phase-2-a-study-of-selinexor-monotherapy-in-subjects-with-jak-inhibitor-nave-myelofibrosis-and-moderate-thrombocytopenia-100514615","NCT05980806","A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","SENTRY-2","Key Inclusion Criteria:\n\n* A diagnosis of MF or post-ET or post-PV MF according to the 2016 World Health Organization (WHO) classification of MPN, confirmed by the most recent local pathology report\n* Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than or equal to (\\>=) 450 cubic square centimeter (cm\\^3) by MRI or CT scan (results from MRI or CT imaging performed within 28 days prior to C1D1 are acceptable)\n* DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or high-risk\n* ECOG Performance Status less than or equal to (\\\u003C=) 2\n* Platelet count of greater than or equal to (\\>=) 50 x 10\\^9\u002FL without platelet transfusion within 7 days prior to the first dose of selinexor\n* Absolute neutrophil count (ANC) \\>=1.0 × 10\\^9\u002FL without need for growth factors within 7 days prior to the first dose of selinexor\n* Adequate liver function as defined by the following: aspartate transaminase (AST) and alanine transaminase (ALT) \\\u003C= 2.5 × upper limit normal (ULN) and serum total bilirubin \\\u003C= 3×ULN\n* Calculated creatinine clearance (CrCl) greater than (\\>) 15 milliliter per minute (mL\u002Fmin) based on the Cockcroft and Gault formula\n* Active symptoms of MF as determined by presence of at least 2 symptoms with an average score \\>= 5 or total score of \\>= 12 at screening (at least 5 of 7 consecutive days immediately preceding C1D1) using the MFSAF V4.0\n* Must provide bone marrow biopsy samples (samples obtained up to 3 months prior to C1D1 are permitted) at screening and during the study\n* Currently not eligible for stem cell transplantation\n* Must be willing to complete the MFSAF V4.0 daily during the study for evaluating the symptom response (i.e., TSS50)\n\nKey Exclusion Criteria:\n\n* More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase)\n* Previous treatment with JAK inhibitors for MF\n* Previous treatment with selinexor or other XPO1 inhibitors\n* Females who are pregnant or lactating\n* Prior splenectomy, splenic radiation, or a splenic embolization within 6 months prior to C1D1\n* History of myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), cerebrovascular accident (transient ischemic attack \\[TIA\\]), ventricular arrhythmias, congestive heart failure class \\> 2 per New York Heart Association (NYHA) within 6 months of C1D1\n* Unable to tolerate two forms of antiemetics prior to each dose for the first two cycles","18 Years",{"count":48,"type":49},58,"ESTIMATED","INTERVENTIONAL",[52],"PHASE2","The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.",[26,55,56],"Moderate Thrombocytopenia","Mild Thrombocytopenia",[26,58,59,60,61,62,63,64,65,66,67,68,69,70],"Selinexor","Total Symptom Score","Myelofibrosis Symptom Assessment Form","Spleen Volume Reduction","TSS50","SVR35","JAK2","KPT-330","Pacritinib","Ruxolitinib","Momelotinib","Thrombocytopenia","Abs-TSS","RECRUITING","2026-02-10",{"date":74,"type":34},"2026-02-12",{"date":76,"type":34},"2024-04-22",{"date":78,"type":49},"2028-10",{"name":36,"class":37},70,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":50,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100394316","phase-2-a-study-of-selinexor-seli--low-dose-dexamethasone-ldd-in-penta-refractory-multiple-myeloma-mm-seli-and-bortezomib--ldd-in-triple-class-refractory-mm-100394316","NCT04414475","A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Age greater than or equal to (\\>=)18 years at the time of signing informed consent.\n* Written informed consent in accordance with federal, local, and institutional guidelines.\n* Measurable MM based on IMWG guidelines as defined by at least one of the following:\n\n  1. Serum M-protein \\>= 0.5 gram per deciliter (g\u002FdL) by serum protein electrophoresis (SPEP) or, for Immunoglobulin (Ig) A myeloma, by quantitative IgA.\n  2. Urinary M-protein excretion \\>= 200 mg\u002F24 hours.\n  3. Free light chain (FLC) \\>= 100 milligram per liter (mg\u002FL), provided that the FLC ratio is abnormal.\n* Only for arms Sd-40 BIW, Sd-100 QW and Sd-80 BIW prior to protocol version (PV) 5.0: Participants must have relapsed or refractory multiple myeloma (RRMM) and have previously received at least 4 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 2 proteasome inhibitors (PIs), at least 2 immunomodulatory agent (IMiDs), and 1 anti-cluster of differentiation (CD38) monoclonal antibody. Refractory is defined as lesser than or equal to (\\\u003C=) 25 percent (%) response to therapy, or progression during therapy or progression within 60 days after completion of therapy.\n* Only for Arms Sd-40 BIW and Sd-100 QW as of PV 5.0: Participants must have RR MM and have been previously treated with \\>=3 anti-MM therapies (with exposure to at least 2 PI drugs, at least 2 IMiDs, and 1 anti-CD38 monoclonal antibody), and be refractory to at least 1 drug of each class (PI\u002FIMiD\u002Fanti-CD38). Refractory is defined as \\\u003C=25% response to therapy or progression during therapy or progression within 60 days after completion of therapy.\n* Only for arm SVd: Participants must have previously received 1 to 5 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 1 PI, at least 1 IMiD, and 1 anti- CD38 monoclonal antibody.\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\\u003C= 2.\n* Female participants of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female participants, effective methods of contraception must be used throughout the study and for 7 months for female and 4 months for male following the discontinuation of study treatment.\n\nExclusion Criteria:\n\n* Active plasma cell leukemia.\n* Documented systemic amyloid light chain amyloidosis.\n* Active central nervous system MM.\n* Only for SVd arm: Greater than Grade 2 peripheral neuropathy or Grade \\>= 2 peripheral neuropathy with pain at baseline, regardless of whether or not the participant is currently receiving medication.\n* Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including investigational therapies) \\\u003C= 2 weeks prior to Cycle 1 Day 1 (C1D1). (Steroids are permitted up to 1 pulse of 40 mg per day for 4 days in the 2 weeks prior to C1D1).\n* Active graft vs. host disease (after allogeneic stem cell transplantation) at C1D1.\n* Ongoing clinically significant non-hematological toxicities from prior treatments that are Grade greater than (\\>) 2 at C1D1.\n* Inadequate hepatic function defined as total bilirubin \\>= 2x upper limit of normal (ULN) (\\>= 3x ULN for participants with Gilbert's syndrome), aspartate transaminase (AST) \\>= 2.5x ULN, and alanine transaminase (ALT) \\>= 2.5x ULN.\n* Inadequate renal function defined as estimated creatinine clearance of lesser than (\\\u003C) 20 milliliter per minute (mL\u002Fmin), calculated using the formula of Cockroft and Gault.\n* Inadequate hematopoietic function defined as the following:\n\n  1. Absolute neutrophil count (ANC) \\\u003C 1000\u002Fcubic millimeter (mm\\^3)\n  2. Platelet count \\\u003C 75,000\u002Fmm\\^3\n  3. Hemoglobin (Hb) level \\\u003C 8.5 g\u002FdL\n* Life expectancy of \\\u003C 4 months, based on the opinion of the Investigator.\n* Major surgery within 4 weeks prior to C1D1.\n* Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose.\n* Active gastrointestinal dysfunction interfering with the ability to swallow tablets, or any gastrointestinal dysfunction that could interfere with absorption of the study treatment.\n* Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus RNA or hepatitis B virus surface antigen.\n* Female participants who are pregnant or lactating.\n* Known intolerance, hypersensitivity, or contraindication to glucocorticoid therapy at C1D1.\n* Concurrent therapy with approved or investigational anticancer therapeutic including topical therapies.\n* Prior exposure to a SINE compound, including selinexor.\n* Serious, active psychiatric or active medical conditions which, in the opinion of the Investigator or the Sponsor, could interfere with the participation in the study.\n* Contraindication to any of the required concomitant drugs or supportive treatments.",{"count":89,"type":49},127,[52],"The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.",[93],"Multiple Myeloma, Refractory",[20,58,95,96,65],"Penta-refractory Multiple Myeloma","Triple-class Refractory Multiple Myeloma","2026-01-30",{"date":99,"type":34},"2026-02-02",{"date":101,"type":34},"2020-07-01",{"date":103,"type":49},"2028-01",{"name":36,"class":37},16,""]